NCT04570644View on ClinicalTrials.gov

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

January 18, 2021

Study Completion Date

January 18, 2021

Conditions
Healthy VolunteersAlzheimer Disease
Interventions
DRUG

ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."

Trial Locations (1)

33014

Panax Clinical Research, Miami Lakes

Sponsors

Lead Sponsor

AZTherapies, Inc.
All Listed Sponsors
lead

AZTherapies, Inc.

INDUSTRY

NCT04570644 - Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter